Quizartinib (AC220): Selective FLT3 Inhibitor for AML Research

Executive Summary: Quizartinib (AC220) is a next-generation, highly selective inhibitor of the FMS-like tyrosine kinase 3 (FLT3) receptor, crucial for acute myeloid leukemia (AML) research. It targets both internal tandem duplication (ITD) and wild-type (WT) FLT3 with nanomolar IC50 values (1.1 nM and 4.2 nM, respectively), exhibiting over ten-fold selectivity compared to related kinases. In vivo, oral doses as low as 1 mg/kg suppress FLT3 activity and tumor growth in mouse xenograft models. Pharmacokinetic profiles show a Cmax of 3.8 μM within two hours post-administration, supporting its use in preclinical settings. Resistance mutations in FLT3 highlight the importance of pathway monitoring in translational studies (Quizartinib A5793 technical sheet).

Biological Rationale

Acute myeloid leukemia (AML) is characterized by uncontrolled proliferation of myeloid precursors. Activating mutations in FLT3, especially ITD mutations, are major drivers in AML pathogenesis, present in approximately 30% of cases (https://doi.org/10.1038/nrc.2017.46). FLT3 signaling promotes cell survival and proliferation via downstream pathways (e.g., STAT5, PI3K/AKT, MAPK). Conventional chemotherapies do not specifically target FLT3, which contributes to high relapse rates. Selective FLT3 inhibition is a validated strategy for dissecting AML biology and testing FLT3-targeted therapeutics (A5793 product page). Quizartinib (AC220) was developed to address the need for potent, selective tools to interrogate FLT3-driven mechanisms in preclinical research. For a broader mechanistic overview, see our recent article on Quizartinib’s in vivo applications; this current review extends that discussion with benchmark parameters and resistance insights.

Mechanism of Action of Quizartinib (AC220)

Quizartinib (AC220) is a second-generation tyrosine kinase inhibitor (TKI) designed for high-affinity binding to FLT3. The compound inhibits FLT3 autophosphorylation, thereby blocking downstream signaling that supports AML cell survival. Quizartinib demonstrates high selectivity, with over ten-fold reduced activity against kinases such as PDGFRα, PDGFRβ, KIT, RET, and CSF-1R (A5793 technical sheet). In cell-based assays, Quizartinib effectively inhibits FLT3 activity and proliferation in AML cell lines (MV4-11, RS4;11) at nanomolar concentrations. The molecule is orally bioavailable, with rapid absorption (Cmax = 3.8 μM at 2 h post-dose, oral, mouse). Detailed mechanistic innovation and translational context are discussed in the article Redefining FLT3 Inhibition; this current review focuses on workflow parameters and resistance mechanisms.

Evidence & Benchmarks

• Quizartinib inhibits FLT3-ITD and FLT3-WT with IC50 values of 1.1 nM and 4.2 nM, respectively, determined in biochemical kinase assays at 25°C in kinase buffer (A5793 sheet).
• Displays >10-fold selectivity for FLT3 versus PDGFRα, PDGFRβ, KIT, RET, and CSF-1R under identical conditions (A5793 datasheet).
• Inhibits proliferation of MV4-11 AML cells (FLT3-ITD+) in vitro at low nanomolar concentrations (IC50 <5 nM) in standard RPMI medium (https://doi.org/10.1182/blood-2008-07-171926).
• Oral administration at 1 mg/kg in mouse FLT3-ITD xenograft models results in significant tumor regression and extended survival (p<0.01) (https://doi.org/10.1182/blood-2008-07-171926).
• Pharmacokinetics: Cmax of 3.8 μM in plasma within 2 hours post-oral dosing (mouse, 10 mg/kg), measured by LC-MS/MS (A5793 datasheet).
• Solubility: ≥28.03 mg/mL in DMSO at 25°C; insoluble in ethanol and water (A5793 datasheet).
• Resistance: Secondary FLT3 mutations (D835, F691L) can confer reduced sensitivity in clinical settings (https://doi.org/10.1038/nrc.2017.46).

Applications, Limits & Misconceptions

Quizartinib (AC220) is intended exclusively for scientific research. It is not approved for diagnostic or therapeutic use in humans. Key applications include:

• FLT3 autophosphorylation inhibition assays in cell-free and cellular systems.
• AML cell viability and proliferation studies.
• In vivo FLT3 inhibition in mouse xenograft models for preclinical drug evaluation.

For a comprehensive molecular discussion of Quizartinib’s precision, see Precision Targeting of FLT3 in AML; this article augments that narrative with benchmark solubility and workflow data.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Quizartinib is highly selective for FLT3; it does not broadly inhibit unrelated kinases.
• Solubility constraints: Insoluble in water or ethanol; must be prepared in DMSO for in vitro or in vivo use.
• Not suitable for long-term stock solutions: Quizartinib solutions degrade; prepare fresh aliquots and use promptly.
• Research use only: Not for human or veterinary diagnostic or therapeutic applications.
• Resistance mutations: Activity is reduced against FLT3 mutants such as D835Y or F691L; routine genotyping is recommended for cell lines or primary samples.

Workflow Integration & Parameters

Reconstitution: Dissolve at ≥28.03 mg/mL in DMSO at 25°C. Vortex and sonicate as needed. Avoid freeze-thaw cycles.

Cellular assay setup: Treat MV4-11 or RS4;11 cells with 1–10 nM Quizartinib in RPMI-1640 containing 10% FBS; incubate 24–72 h at 37°C, 5% CO₂.

In vivo dosing: Typical oral doses range from 1–10 mg/kg in mouse models; administer via oral gavage in 0.5% methylcellulose/0.1% Tween-80 vehicle (A5793 technical sheet).

Storage: Store solid at -20°C. Avoid light and moisture. Use freshly prepared solutions to maintain potency.

Analytical quantification: Use LC-MS/MS for plasma or tissue quantification. Peak plasma levels (Cmax) are typically observed within 2 hours post-dose.

For protocols and troubleshooting tips, see the advanced guidance in Advancing FLT3 Inhibitor Research; the present article adds workflow benchmarks and pitfalls.

Conclusion & Outlook

Quizartinib (AC220) is a validated, highly selective FLT3 inhibitor for AML research, offering nanomolar potency and robust in vivo activity. Its use requires careful consideration of solubility, storage, and resistance mutations. As resistance mechanisms continue to emerge, Quizartinib remains a key tool for dissecting FLT3-driven oncogenic processes and benchmarking new inhibitor strategies. For up-to-date technical data, reference the Quizartinib (AC220) A5793 product page.